The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-26. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
== R == r-selection – radiobiology – receptor (biochemistry) – receptor (immunology) – recombination – Red Queen – redox reaction – redox system – reduction – reflex – Renal corpuscle – repeats – replication bubble – repressor – reproduction – reproductive system – respiration (physiology) – restriction enzyme – retrovirus – reverse genetics – RFLP – Rh blood group system – ribosome – RNA – RNA virus – Robert Koch – root – rough ER – RuBP – Rudolf Steiner –
A common example of backpressure is that caused by the exhaust system (consisting of the exhaust manifold, catalytic converter, muffler and connecting pipes) of an automotive four-stroke engine, which has a negative effect on engine efficiency, resulting in a decrease of power output that must be compensated by increasing fuel consumption. In a piston-ported two-stroke engine, however, the situation is more complicated, due to the need to prevent unburned fuel/air mixture from passing right through the cylinders into the exhaust. During the exhaust phase of the cycle, backpressure is even more undesirable than in a four-stroke engine, as there is less time available for exhaust and the lack of pumping action from the piston to force the exhaust out of the cylinder. However, since the exhaust port necessarily remains open for a time after scavenging is completed, unburned mixture can follow the exhaust out of the cylinder, wasting fuel and increasing pollution. This can only be prevented if the pressure at the exhaust port is greater than that in the cylinder. Since the timing of this process is determined mainly by exhaust system geometry, which is extremely difficult to make variable, correct timing and therefore optimum engine efficiency can typically only be achieved over a small part of the engine's range of operating speed.
Preventive medications may be recommended for those experiencing frequent or severe migraines. In particular, preventative drugs are recommended for individuals that experience more than 4 migraines per month, as well as for those where acute treatment does not work well. Preventive medications include beta blockers, topiramate, and calcitonin gene related peptides (CGRP) inhibitors like erenumab and galcanezumab. According to the European Headache Federation and American Headache Society, CGRP targeting therapies—which include both gepants and monoclonal antibodies—are a first-line option for migraine prevention. Botox injections can also help prevent migraine attacks, and are sometimes used for chronic migraines when other medications fail. For predicable menstrual migraines, a further option for prevention exist: the use of triptans in the two days before the period starts until three days after, or on the day the migraine is anticipated. This approach can be combined with other preventative drugs.
Hamilton, 1822) (great snakehead) Channa melanoptera (Bleeker, 1855) Channa melanostigma Geetakumari & Vishwanath Waikhom, 2011 Channa melasoma (Bleeker, 1851) (black snakehead) Channa micropeltes (G. Cuvier, 1831) (giant snakehead) Channa ninhbinhensis V. H. Nguyễn, 2011 Channa nox C. G. Zhang, Musikasinthorn & Watanabe, 2002 (night snakehead) Channa orientalis Bloch & J. G. Schneider, 1801 (Ceylon snakehead) Channa ornatipinnis Britz, 2008 Channa panaw Musikasinthorn, 1998 (Panaw snakehead) Channa pardalis Knight, 2016 Channa pleurophthalma (Bleeker, 1851) Channa pomanensis Gurumayum & Tamang, 2016 Channa pseudomarulius (Günther, 1861) Channa pulchra Britz, 2007 Channa punctata (Bloch, 1793) (spotted snakehead) Channa pyrophthalmus Ralf Britz, Tan Heok Hui, & Lukas Rüber, 2024 Channa quinquefasciata Praveenraj et al., 2018 Channa rakhinica Ralf Britz, Tan Heok Hui, & Lukas Rüber, 2024 Channa rara Britz, Dahanukar, Anoop & Ali, 2019 Channa royi Praveenraj et al., 2018 (Andaman emerald snakehead) — likely a synonym of C. harcourtbutleri Channa rubora Ralf Britz, Tan Heok Hui, & Lukas Rüber, 2024 Channa shingon M. Endruweit, 2017) Channa stewartii (Playfair (fr), 1867) (Assamese snakehead) Channa stiktos Lalramliana, Knight, Lalhlimpuia & Singh, 2018 Channa striata (Bloch, 1793) (striped snakehead)
Unlike standard supply-chain management practices world-wide, some major concepts are not supported in the military domain. For example, the "just-in-time" (JIT) model emphasizes holding less (or no) inventory, whereas in military supply chains, due to the high costs of a stock-out (potentially placing lives in danger), keeping huge inventory is a more acceptable practice. Some examples of these are the ammunition dump and oil depot. Likewise, the military procurement process has much different criteria than the normal business procurement process. Military needs call for reliability of supply during both peace and war, as compared to price and technological factors.
Sources: en.wikipedia.org
During 1973–2013, Khavinson et al., extracted from various organs over 20 complexes of physiologically active peptides, as well as 15 others synthesized from amino acids, (di-, tri-, tetrapeptides), all being covered by patents in many countries including the US, Canada, Australia, Europe, Japan, Korea, Israel, etc. After many years of experimental and clinical studies, six medicinal peptide preparations were permitted for medical use in the USSR, Russia, and afterward in the CIS countries. They were primarily to be used by the military medical service. These are ‘Thymalin’- a preparation of the thymus, being a cellular immunity regulator; ‘Epithalamin’ — a preparation from the pineal gland — regulator of the endocrine system, which restores melatonin, (with no analogues worldwide) ‘Cortexin’ — a preparation from the cerebral cortex, brain function regulator; ‘Prostatilen’ or ‘Samprost’ or ‘Vitaprost’ — a preparation from the prostate gland, regulator of prostate function; ‘Retinalamin’ — a preparation from the retina, partially restores functions of the retina in case of laser lesions and degenerative diseases, has no analogues worldwide; ‘Thymogen’ — a dipeptide EW, being first extracted from ‘Thymalin’, then synthesized from amino acids, regulates immunity. These medicinal peptide preparations were first used to restore immune functions of the brain, endocrine system, retina, etc.
== Multi-chain polymerization == A monomer with functionality 3 has 3 functional groups that participate in the polymerization. This will introduce branching in a polymer and may ultimately form a cross-linked macrostructure. The point at which this three-dimensional 3D network is formed is known as the gel point, signaled by an abrupt change in viscosity. A more general functionality factor fav is defined for multi-chain polymerization, as the average number of functional groups present per monomer unit. For a system containing N0 molecules initially and equivalent numbers of two function groups A and B, the total number of functional groups is N0fav.
The mechanism for this form of recombination and repair have been linked to the nucleotide excision repair (NER) pathway playing a role in recognizing and repairing triplex structures. Multiple investigations suggests that the xeroderma pigmentosum group A (XPA) and replication protein A (RPA), which are NER factors, are able to bind specifically as a complex to cross-linked triplex structures. It is known that this mechanism alongside others play a role in recognizing and repairing triplex structures. The in vivo delivery of TFOs has been a major barrier in using TFOs for gene modification. One study on in vivo targeting of hematopoietic stem cells proposed a novel technique of conjugating PNA molecules with cell penetrating peptide (CPPs) alongside poly(lactic-co-glycolic acid) (PLGA) nanoparticles to enable 6 bp modifications in the CCR5 gene. The editing of the CCR5 gene has been linked to HIV-1 resistance. CPPs are proteins that are able to carry "cargo" such as small proteins or molecules successfully into cells. The PGLAs are biodegradable material that encapsulate PNA molecules as nanoparticles for site specific genome modifications. The study found that the PNA-DNA PGLA nanoparticles were able to effectively edit the hematopoietic stem cells with lower toxicity and virus-free and the conjugation with CPP offered direct targeting of the genes for site-specific mutagenesis in the stem cells.
A skeleton is the structural frame that supports the body of most animals. There are several types of skeletons, including the exoskeleton, which is a rigid outer shell that holds up an organism's shape; the endoskeleton, a rigid internal frame to which the organs and soft tissues attach; and the hydroskeleton, a flexible internal structure supported by the hydrostatic pressure of body fluids. Vertebrates are animals with an endoskeleton centered around an axial vertebral column, and their skeletons are typically composed of bones and cartilages. Invertebrates are other animals that lack a vertebral column, and their skeletons vary, including hard-shelled exoskeleton (arthropods and most molluscs), plated internal shells (e.g. cuttlebones in some cephalopods) or rods (e.g. ossicles in echinoderms), hydrostatically supported body cavities (most), and spicules (sponges). Cartilage is a rigid connective tissue that is found in the skeletal systems of vertebrates and invertebrates.
=== Transit === On December 16, 2025, Pritzker signed into law the Illinois People Over Parking Act, which disburses $1.5 billion to address post-COVID-19 budget shortfalls for Chicagoland-area transit authorities to avoid service cuts; reduces the farebox revenue share of total funding from 50% to 25%, since post-pandemic reductions in ridership made these expectations unreasonable; and disburses $169 million to downstate transit agencies to cover similar budget shortfalls. It prevents transit agencies from transferring funding for operations to capital investment. Local jurisdictions are prohibited from establishing minimum parking requirements within half a mile of transit rail stations and bus hubs or one-eighth mile of corridors with combined bus route frequency of 15 minutes or less during peak periods under this legislation. The bill also reorganizes the Regional Transportation Authority into the Northern Illinois Transit Authority, which is intended to centralize decision-making power away from individual counties and synchronize operations of the Chicago Transit Authority, Metra, and Pace. The NITA board is to have 20 members, five assigned by the mayor of Chicago, the Cook County President, and the governor, and five by the five collar counties, where 15 votes are needed to affirm board actions, or 12 if two affirmative votes from each of the four appointing authorities are cast; and a majority of CTA, Metra, and Pace board members are to be simultaneously staffed by NITA board members.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.